The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial

Ann Ophthalmol (Skokie). 2009 Fall-Winter;41(3-4):174-8.

Abstract

We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Agonists / administration & dosage
  • Antihypertensive Agents / administration & dosage
  • Brimonidine Tartrate
  • Carbonic Anhydrase Inhibitors / administration & dosage
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Glaucoma, Open-Angle / drug therapy*
  • Glaucoma, Open-Angle / physiopathology
  • Humans
  • Intraocular Pressure / drug effects*
  • Male
  • Middle Aged
  • Ocular Hypertension / drug therapy
  • Ocular Hypertension / physiopathology
  • Ophthalmic Solutions
  • Prospective Studies
  • Quinoxalines / administration & dosage*
  • Sulfonamides / administration & dosage*
  • Thiophenes / administration & dosage*
  • Time Factors
  • Timolol / administration & dosage*
  • Treatment Outcome

Substances

  • Adrenergic alpha-Agonists
  • Antihypertensive Agents
  • Carbonic Anhydrase Inhibitors
  • Drug Combinations
  • Ophthalmic Solutions
  • Quinoxalines
  • Sulfonamides
  • Thiophenes
  • Brimonidine Tartrate
  • Timolol
  • dorzolamide